Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 60,000 shares at $107.22 ($6.4M) on 2026-09-09, disclosed to the SEC on 2026-09-11.
Scheduled sale ($6.4M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $107.22 | 13,304 | $1.4M | 22.2% |
| 2 | $107.82 | 6,596 | $711K | 11.0% |
| 3 | $108.67 | 100 | $11K | 0.2% |
| 4 | $107.01 | 14,588 | $1.6M | 24.3% |
| 5 | $107.58 | 5,412 | $582K | 9.0% |
| 6 | $107.15 | 15,492 |
| $1.7M |
| 25.8% |
| 7 | $107.55 | 4,508 | $485K | 7.5% |
| Total | $107.28 avg | 60,000 | $6.4M | 100% |
| Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |
| HALO | SELL | 2026-05-13 | $3.4M | — | Filing → |